366 related articles for article (PubMed ID: 34101869)
1. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.
Cho K; Ro SW; Lee HW; Moon H; Han S; Kim HR; Ahn SH; Park JY; Kim DY
Hepatology; 2021 Nov; 74(5):2605-2621. PubMed ID: 34101869
[TBL] [Abstract][Full Text] [Related]
2. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
[TBL] [Abstract][Full Text] [Related]
3. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.
Saito Y; Yin D; Kubota N; Wang X; Filliol A; Remotti H; Nair A; Fazlollahi L; Hoshida Y; Tabas I; Wangensteen KJ; Schwabe RF
Gastroenterology; 2023 Jun; 164(7):1279-1292. PubMed ID: 36894036
[TBL] [Abstract][Full Text] [Related]
4. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
5. SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
Yuan T; Zhou T; Qian M; Du J; Liu Y; Wang J; Li Y; Fan G; Yan F; Dai X; Li X; Wu Y; Dong X; He Q; Zhu H; Yang B
Hepatology; 2023 Jul; 78(1):103-119. PubMed ID: 35713976
[TBL] [Abstract][Full Text] [Related]
6. Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway.
Kong D; Jiang Y; Miao X; Wu Z; Liu H; Gong W
Biochim Biophys Acta Mol Basis Dis; 2021 Dec; 1867(12):166267. PubMed ID: 34508829
[TBL] [Abstract][Full Text] [Related]
7. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization.
Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z
Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992
[TBL] [Abstract][Full Text] [Related]
8. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
Wang H; Zhang S; Zhang Y; Jia J; Wang J; Liu X; Zhang J; Song X; Ribback S; Cigliano A; Evert M; Liang B; Wu H; Calvisi DF; Zeng Y; Chen X
J Hepatol; 2022 Jan; 76(1):123-134. PubMed ID: 34464659
[TBL] [Abstract][Full Text] [Related]
9. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
Wang H; Wang J; Zhang S; Jia J; Liu X; Zhang J; Wang P; Song X; Che L; Liu K; Ribback S; Cigliano A; Evert M; Wu H; Calvisi DF; Zeng Y; Chen X
Cell Mol Gastroenterol Hepatol; 2021; 11(4):1095-1117. PubMed ID: 33232824
[TBL] [Abstract][Full Text] [Related]
10. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition.
Yan B; Li T; Shen L; Zhou Z; Liu X; Wang X; Sun X
Biochem Biophys Res Commun; 2019 Jul; 515(2):275-281. PubMed ID: 31146919
[TBL] [Abstract][Full Text] [Related]
12. Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury.
Konishi T; Schuster RM; Lentsch AB
Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G471-G482. PubMed ID: 29351389
[TBL] [Abstract][Full Text] [Related]
13. The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness.
Park H; Lee Y; Lee K; Lee H; Yoo JE; Ahn S; Park YN; Kim H
Pathol Oncol Res; 2021; 27():604600. PubMed ID: 34257565
[No Abstract] [Full Text] [Related]
14. Transcatheter arterial chemoembolization combined with Hippo/YAP inhibition significantly improve the survival of rats with transplanted hepatocellular carcinoma.
Quan Y; Li Z; Zhu K; Liang J
Lipids Health Dis; 2021 Jul; 20(1):74. PubMed ID: 34304741
[TBL] [Abstract][Full Text] [Related]
15. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.
Marquard S; Thomann S; Weiler SME; Bissinger M; Lutz T; Sticht C; Tóth M; de la Torre C; Gretz N; Straub BK; Marquardt J; Schirmacher P; Breuhahn K
Cell Commun Signal; 2020 Oct; 18(1):166. PubMed ID: 33097058
[TBL] [Abstract][Full Text] [Related]
16. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
17. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.
Sun T; Mao W; Peng H; Wang Q; Jiao L
Cell Oncol (Dordr); 2021 Jun; 44(3):689-699. PubMed ID: 33655469
[TBL] [Abstract][Full Text] [Related]
18. The calcimimetic agent cinacalcet inhibits hepatocellular carcinoma via YAP/TAZ suppression.
Zheng L; Du J; Ge F; Qian M; Yang B; He Q; Weng Q; Zhu H
Pharmazie; 2021 Oct; 76(10):511-514. PubMed ID: 34620281
[TBL] [Abstract][Full Text] [Related]
19. YAP activation is an early event and a potential therapeutic target in liver cancer development.
Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
[TBL] [Abstract][Full Text] [Related]
20. Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.
Dai XY; Zhuang LH; Wang DD; Zhou TY; Chang LL; Gai RH; Zhu DF; Yang B; Zhu H; He QJ
Oncotarget; 2016 Feb; 7(6):6933-47. PubMed ID: 26771844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]